ATE213836T1 - Verfahren zur herstellung von diagnostischen reagentien, testverfahren und medikamenten, die auf den klinischen manifestationen einer krankheit beruhen - Google Patents

Verfahren zur herstellung von diagnostischen reagentien, testverfahren und medikamenten, die auf den klinischen manifestationen einer krankheit beruhen

Info

Publication number
ATE213836T1
ATE213836T1 AT95902582T AT95902582T ATE213836T1 AT E213836 T1 ATE213836 T1 AT E213836T1 AT 95902582 T AT95902582 T AT 95902582T AT 95902582 T AT95902582 T AT 95902582T AT E213836 T1 ATE213836 T1 AT E213836T1
Authority
AT
Austria
Prior art keywords
antibodies
disease
peptides
molecules
bound
Prior art date
Application number
AT95902582T
Other languages
English (en)
Inventor
Daniel V Santi
Original Assignee
Daniel V Santi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daniel V Santi filed Critical Daniel V Santi
Application granted granted Critical
Publication of ATE213836T1 publication Critical patent/ATE213836T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95902582T 1993-11-19 1994-11-17 Verfahren zur herstellung von diagnostischen reagentien, testverfahren und medikamenten, die auf den klinischen manifestationen einer krankheit beruhen ATE213836T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/155,943 US5492807A (en) 1993-11-19 1993-11-19 Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
PCT/US1994/013241 WO1995014110A1 (en) 1993-11-19 1994-11-17 Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease

Publications (1)

Publication Number Publication Date
ATE213836T1 true ATE213836T1 (de) 2002-03-15

Family

ID=22557410

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902582T ATE213836T1 (de) 1993-11-19 1994-11-17 Verfahren zur herstellung von diagnostischen reagentien, testverfahren und medikamenten, die auf den klinischen manifestationen einer krankheit beruhen

Country Status (11)

Country Link
US (2) US5492807A (de)
EP (2) EP1150121A3 (de)
JP (1) JP3135126B2 (de)
AT (1) ATE213836T1 (de)
AU (1) AU674471B2 (de)
CA (1) CA2175374A1 (de)
DE (1) DE69429999T2 (de)
DK (1) DK0729517T3 (de)
ES (1) ES2173165T3 (de)
PT (1) PT729517E (de)
WO (1) WO1995014110A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US5492807A (en) * 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
ITPN960013A1 (it) * 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
WO2000023140A1 (en) 1998-10-16 2000-04-27 Mission Medical, Inc. Blood processing system
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
EP1315512A4 (de) 2000-09-08 2005-11-09 Univ Texas Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) * 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
EP1418932A4 (de) * 2001-07-18 2006-03-15 Univ Texas Antiangiogener zustand bei mäusen und menschen mit retinaler photorezeptor-degeneration
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7863004B2 (en) * 2001-12-04 2011-01-04 Wayne State University Neoepitope detection of disease using protein arrays
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
AU2003903317A0 (en) * 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
WO2006060171A2 (en) * 2004-11-16 2006-06-08 Board Of Regents, The University Of Texas System Methods and compositions related to phage-nanoparticle assemblies
US20090221505A1 (en) * 2004-11-16 2009-09-03 Mikhail Kolonin Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
DK3903829T3 (da) 2009-02-13 2023-06-26 Immunomedics Inc Immunkonjugater med en intracellulær spaltelig binding
EP2525820B1 (de) 2010-01-19 2016-05-11 Immunomedics, Inc. Neue klasse monospezifischer und bispezifischer humanisierter antikörper zur anzielung des insulinähnlichen wachstumsfaktorrezeptors vom typ 1 (igf-1r)
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
EP3083700B1 (de) 2013-12-17 2023-10-11 The Brigham and Women's Hospital, Inc. Bestimmung eines antikörpers gegen ein pathogen
CN106999517A (zh) 2014-10-07 2017-08-01 免疫医疗公司 抗体‑药物缀合物的新辅助剂用途
PL3313443T3 (pl) 2015-06-25 2023-11-06 Immunomedics, Inc. Łączenie przeciwciał anty-hla-dr lub anty-trop-2 z inhibitorami mikrotubuli, inhibitorami parp, 5 inhibitorami kinazy brutona lub inhibitorami 3-kinazy fosfoinozytydu istotnie poprawia wynik terapeutyczny nowotworu
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119760B2 (ja) * 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
WO1986006487A1 (en) * 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US5492807A (en) * 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease

Also Published As

Publication number Publication date
EP0729517A4 (de) 1997-10-15
JPH09500731A (ja) 1997-01-21
EP1150121A2 (de) 2001-10-31
AU674471B2 (en) 1996-12-19
PT729517E (pt) 2002-08-30
AU1180495A (en) 1995-06-06
US5670312A (en) 1997-09-23
DE69429999D1 (de) 2002-04-04
ES2173165T3 (es) 2002-10-16
EP0729517A1 (de) 1996-09-04
CA2175374A1 (en) 1995-05-26
EP0729517B1 (de) 2002-02-27
JP3135126B2 (ja) 2001-02-13
US5492807A (en) 1996-02-20
EP1150121A3 (de) 2004-01-07
DK0729517T3 (da) 2002-04-22
DE69429999T2 (de) 2002-08-29
WO1995014110A1 (en) 1995-05-26

Similar Documents

Publication Publication Date Title
ATE213836T1 (de) Verfahren zur herstellung von diagnostischen reagentien, testverfahren und medikamenten, die auf den klinischen manifestationen einer krankheit beruhen
ATE346303T1 (de) Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden
DE69005270T2 (de) Verfahren zur optischen analyse.
DE69020143T2 (de) Verfahren zur verwendung und herstellung von peptiden.
ATE397660T1 (de) Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
WO1995018826A3 (en) Purified primate ctla-8 antigens and related reagents
ATE123653T1 (de) Vernetzte antikörper und verfahren zu ihrer herstellung.
DE69030947D1 (de) Monoklonaler Antikörper spezifisch für ein humanes atherom-assoziiertes Antigen
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
DE69002623T2 (de) Verfahren zur abtrennung und reinigung von sialyl-transferasen.
DE3865678D1 (de) Satz und verfahren zur diagnose der iga-nephropathie.
DE69616563T2 (de) Verfahren zur diagnose von autoimmunerkrankungen
ATE123952T1 (de) Vernetzte antikörper und verfahren zu ihrer herstellung.
DE68921374T2 (de) Monoklonaler Antikörper gegen menschliche Mangan-Superoxiddismutase, Verfahren zu dessen Herstellung, Testreagens, Kit und Testmethode unter Verwendung desselben, Verfahren zur Diagnose von menschlichem Eierstockkrebs und von Herzinfarkt.
RU2005108044A (ru) Эпитопы т-клеток в стафилококковом энтеротоксине в
ATE265533T1 (de) Saeugetierchemokine
DE69534178D1 (en) S?ugetier thymokingene
ATE352037T1 (de) Immunochromatographiesystem und verfahren zur gleichzeitigen identifikation von aga-und t-tg- antikörpern und verwendung dafür zur diagnose der zöliakiekrankheit
Hauser Human immunogenetics: Basic principles and clinical relevance. Immunology series. Volume 43: Edited by Stephen D. Litwin. New York: Marcel dekker, inc.(1989). 856 pp. $150.00
Borek Immunochemical methods in cell and molecular biology: Mayer, RJ and Walker JH, xiv+ 326 pp. Academic Press, London, 1987.£ 26.00, ISBN 0-12-480455-7
MYCROFT NEUROACTIVE PEPTIDES FROM MILK AND WHEAT PROTEINS (MIF, HALOPERIDOL, SCHIZOPHRENIA)
Borek Human retroviruses, cancer, and AIDS: Approaches to prevention and therapy: Bolognesi, D.(Ed.), 524 pp. Alan R. Liss, New York, 1987. $96.00, ISBN 0-8451-2670-9
IT8748142A0 (it) Metodo diagnostico basato sull'impiego di anticorpi ed antigeni specificatamente adatti a rivelare i processi di denaturazione proteica e la conseguente reazione autoimmunitaria che stanno alla base di alcune malattie autoimmunitarie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee